Shots:
- Following the successful completion of the interim analysis from the P-I & P-II clinical trials of Covaxin, the company has received the DCGI approval to conduct a P-III study of its COVID-19 vaccine
- The study will assess Covaxin (6mcg, IM at an interval of 28days) vs PBO in ~26,000 volunteers in a ratio (1:1) aged ≥18yrs. in over 25 centers across India and is being conducted in partnership with ICMR. It is the largest clinical trial conducted for a COVID-19 vaccine in India
- Bharat Biotech plans to launch Covaxin by June’2021, unless the government decides to give the vaccine a EUA before that, based on data from earlier phases of clinical trial
Source 1, Source 2 to read full press release/ article | Ref: Bharat Biotech, NDTV | Image: MediCircle
The post Bharat Biotech Initiates P-III Study for Covaxin Against COVID-19 first appeared on PharmaShots.
